Back to Search Start Over

Azurity Pharma gets US FDA approval for Danziten tablets, the first and only nilotinib with no mealtime restrictions

Source :
PharmaBiz. November 16, 2024
Publication Year :
2024

Abstract

Azurity Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Danziten, the first and only nilotinib with no mealtime restrictions indicated for adult patients with newly diagnosed [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.816471561